Genees Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
- Paid Up Capital ₹ 2.95 M
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 50.03%
- Profit Growth 24.47%
- Ebitda 29.57%
- Net Worth 117.12%
- Total Assets 51.22%
About Genees Pharmaceutical
Genees Pharmaceutical Private Limited (GPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 August 2012 and has a history of 12 years and five months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.95 M, as per Ministry of Corporate Affairs (MCA) records.
Sagar Gurav, Sameer Waghmare, Ravindra Zare, and Two other members serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24234PN2012PTC144352
- Company No.
144352
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Genees Pharmaceutical?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sagar Gurav  | Director | 11-Jun-2019 | Current |
| Sameer Waghmare | Director | 05-Aug-2019 | Current |
| Ravindra Zare | Director | 05-Aug-2019 | Current |
| Vishal Kagdelwar | Director | 05-Aug-2019 | Current |
| Vishwas Bajare | Director | 05-Aug-2019 | Current |
Financial Performance of Genees Pharmaceutical.
Genees Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 50.03% increase. The company also saw a substantial improvement in profitability, with a 24.47% increase in profit. The company's net worth Soared by an impressive increase of 117.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genees Pharmaceutical?
In 2023, Genees Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Boroza Pharmaceutical Private LimitedSagar Gurav, Ravindra Zare and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genees Pharmaceutical?
Genees Pharmaceutical has a workforce of 46 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genees Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genees Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
